Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on December 23rd and 24th, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, President of Gyre Therapeutics, sold shares of the company's common stock on December 23rd and 24th, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• On December 23rd, 1,704 shares were sold at a weighted average price of $12.24, with individual prices ranging from $11.40 to $12.39.
• An additional 296 shares were sold on December 23rd at a weighted average price of $12.44, with individual prices ranging from $12.41 to $12.48.
• On December 24th, 2,000 shares were sold at a weighted average price of $11.93, with individual prices ranging from $11.76 to $12.09.
• Following these transactions, Mr. Ma continues to beneficially own 2,930,467 shares indirectly through his spouse.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock sales under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Insider selling can sometimes be viewed negatively by investors, but the existence of a pre-arranged 10b5-1 trading plan suggests the sales were planned in advance and not based on any material non-public information. It is common for executives to use these plans for diversification or liquidity purposes.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates